Engineering human rhinovirus serotype-A1 as a vaccine vector

Virus Res. 2015 May 4:203:72-6. doi: 10.1016/j.virusres.2015.04.002. Epub 2015 Apr 11.

Abstract

Herein we describe the construction of recombinant human rhinoviruses (rHRVs) encoding HIV Gag or Tat by inserting the full length tat gene or regions of the gag gene flanked by sequences encoding the HRV 2A protease cleavage site into the junction between HRV genes encoding structural (P1) and non-structural (P2) proteins. Most recombinants were unstable, but this was corrected by mutation of the flanking cleavage sites. Thereafter, all rHRV constructs retained the inserts throughout six passages. Such constructs may find utility as vaccine vectors to generate mucosal immunity.

Keywords: HIV Gag; HIV Tat; Human rhinovirus A1; Vaccine vector.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / genetics*
  • Drug Carriers*
  • Genetic Engineering*
  • Genetic Vectors*
  • Humans
  • Recombination, Genetic*
  • Rhinovirus / genetics*
  • Vaccines, Synthetic / genetics
  • gag Gene Products, Human Immunodeficiency Virus / genetics
  • tat Gene Products, Human Immunodeficiency Virus / genetics

Substances

  • AIDS Vaccines
  • Drug Carriers
  • Vaccines, Synthetic
  • gag Gene Products, Human Immunodeficiency Virus
  • tat Gene Products, Human Immunodeficiency Virus